<SEC-DOCUMENT>0001104659-21-121247.txt : 20210930
<SEC-HEADER>0001104659-21-121247.hdr.sgml : 20210930
<ACCEPTANCE-DATETIME>20210930163227
ACCESSION NUMBER:		0001104659-21-121247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210928
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210930
DATE AS OF CHANGE:		20210930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEALTHEQUITY, INC.
		CENTRAL INDEX KEY:			0001428336
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36568
		FILM NUMBER:		211295437

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020
		BUSINESS PHONE:		801-727-1000

	MAIL ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHEQUITY INC
		DATE OF NAME CHANGE:	20080227
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2128876d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:hqy="http://healthequity.com/20210928">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_hqy_healthequity.com_20210928 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20210928_20210928 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001428336 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityCentralIndexKey">0001428336</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hqy-20210928.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-09-28to2021-09-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001428336</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-28</xbrli:startDate>
        <xbrli:endDate>2021-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form&#160;<span id="xdx_903_edei--DocumentType_c20210928__20210928_zDRARrg6wRuh"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--DocumentPeriodEndDate_c20210928__20210928_zGNtrusp969k"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 28, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20210928__20210928_zcg7aqpMYqP5"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityRegistrantName">HEALTHEQUITY,&#160;INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20210928__20210928_z9Ki5O5rYBY8"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_908_edei--EntityFileNumber_c20210928__20210928_zNfno3ZT6hCh"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityFileNumber">001-36568</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20210928__20210928_zxIXRGFD8qN6"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityTaxIdentificationNumber">52-2383166</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(State
    or other jurisdiction of<br /> incorporation or organization)</b></span></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Commission
    File Number)</b></span></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(I.R.S.
    Employer<br /> Identification Number)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20210928__20210928_zPhy9lfeA48h"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressAddressLine1">15 West Scenic Pointe Drive</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine2_c20210928__20210928_zxlml3XAq2D9"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressAddressLine2">Suite&#160;100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20210928__20210928_z6tFnOqDLUxj"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressCityOrTown">Draper</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20210928__20210928_zN1JIcjEbmtd"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20210928__20210928_z0PqdySdnNSf"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressPostalZipCode">84020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90B_edei--CityAreaCode_c20210928__20210928_z2lI4AN6P6p"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:CityAreaCode">801</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20210928__20210928_zXiy7YJxVJba"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:LocalPhoneNumber">727-1000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address, including Zip Code, and Telephone
Number, including Area Code, of Registrant&#8217;s Principal Executive Offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: left; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--WrittenCommunications_c20210928__20210928_zYANstkI9oD"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities
Act (17 CFR 230.425)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--SolicitingMaterial_c20210928__20210928_zKpkT9unoTT"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange
Act (17 CFR 240.14a-12)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--PreCommencementTenderOffer_c20210928__20210928_zF3am9N2XOP8"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20210928__20210928_zqBkXODCMbKf"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 37%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 26%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--Security12bTitle_c20210928__20210928_z8mBgOzwAilj"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:Security12bTitle">Common stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20210928__20210928_zc5tgcNPC9Af"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:TradingSymbol">HQY</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SecurityExchangeName_c20210928__20210928_zPOQ0y6Kkhw2"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17
CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0; text-align: right; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20210928__20210928_z7mQsyaDHRmi"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&#160;28, 2021, HealthEquity,&#160;Inc. (the
&#8220;Company&#8221;) and certain of its subsidiaries entered into a purchase agreement with the representative of the initial
purchasers named therein (the "Purchase Agreement"), pursuant to which the Company agreed to sell $500 million aggregate principal
amount of its 4.500% Senior Notes due 2029 at an issue price of 100% of their aggregate principal amount. The offering is expected
to close on October&#160;8, 2021, subject to customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations, warranties
and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the initial purchasers,
other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Purchase Agreement is attached as Exhibit&#160;1.1 hereto
and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the net proceeds from the offering, together
with cash on hand and borrowings under new credit facilities, to refinance outstanding amounts under its existing term loan and/or for
general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Exhibit&#160;No.</span></b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2128876d1_ex1-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2128876d1_ex1-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Purchase Agreement, dated as of September&#160;28, 2021, between the Company and J.P. Morgan Securities LLC as Representative of the several Initial Purchasers listed in Schedule 1 thereto.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Cover Page&#160;Interactive Data File (formatted in Inline XBRL)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><b>HEALTHEQUITY,&#160;INC.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Date: September 30,
    2021</span></td>
    <td style="vertical-align: bottom; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Tyson Murdock</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">Tyson Murdock</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LppWRO2jRUWsIkXE19huJdhmyyb+HclbGlvEZWFZZr4ZIUKxoqWukeE0zzM4YNPWyiHkWCGjKdA70vUmAX9zvGjrWBnXvT8wJc+gZ8YDeS680Fnv2mKZgJwMR9EwmoGcJnEM+60IvnpKptIlGqdVDcqUsGdqWaNT/OoTDupJhppXV3VEtppMAtFA9vIbYhnFsKO7ehBfLWRZKoKwm0CsmG7tt+ZmHTWwqLHxXbZH/xt8AD1TSYE= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2128876d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$500,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HEALTHEQUITY,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">4.500% Senior Notes due 2029</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Purchase Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 6in">September&nbsp;28, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">As Representative of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">several Initial Purchasers listed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">in Schedule 1 hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HealthEquity,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the &ldquo;<U>Initial
Purchasers</U>&rdquo;), for whom you are acting as representative (the &ldquo;<U>Representative</U>&rdquo;), $500,000,000 principal amount
of its 4.500% Senior Notes due 2029 (the &ldquo;<U>Securities</U>&rdquo;). The Securities will be issued pursuant to an Indenture to be
dated as of October&nbsp;8, 2021 (the &quot;<U>Indenture</U>&quot;), among the Company, the guarantors listed in Schedule 2 hereto (the
 &ldquo;<U>Guarantors</U>&rdquo;) and Wells Fargo Bank, National Association, as trustee (the &ldquo;<U>Trustee</U>&rdquo;), and will be
guaranteed on an unsecured basis by each of the Guarantors (the &ldquo;<U>Guarantees</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and the Guarantors hereby confirm their agreement with
the several Initial Purchasers concerning the purchase and resale of the Securities, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><U>Offering Memorandum and Transaction Information</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities will be sold to the Initial Purchasers without being
registered under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), in reliance upon an exemption therefrom.
The Company and the Guarantors have prepared a preliminary offering memorandum dated September&nbsp;28, 2021 (the &ldquo;<U>Preliminary
Offering Memorandum</U>&rdquo;) and will prepare an offering memorandum dated the date hereof (the &ldquo;<U>Offering Memorandum</U>&rdquo;)
setting forth information concerning the Company, the Guarantors and the Securities. Copies of the Preliminary Offering Memorandum have
been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this
purchase agreement (the &ldquo;<U>Agreement</U>&rdquo;). The Company hereby confirms that it has authorized the use of the Preliminary
Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection with the offering
and resale of the Securities by the Initial Purchasers in the manner contemplated by this Agreement. Except where expressly stated otherwise
herein, references herein to the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum shall be deemed
to refer to and include any document incorporated by reference therein and any reference to &ldquo;amend,&rdquo; &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Preliminary Offering Memorandum or the Offering Memorandum shall be deemed to refer to
and include any documents filed after such date and incorporated by reference therein. Capitalized terms used but not defined herein shall
have the meanings given to such terms in the Preliminary Offering Memorandum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 10%">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to 3:45 p.m.&nbsp;New York City time
on September&nbsp;28, 2021, the time when sales of the Securities were first made (the &ldquo;<U>Time of Sale</U>&rdquo;), the Company
had prepared the following information (collectively, the &ldquo;<U>Time of Sale Information</U>&rdquo;): the Preliminary Offering Memorandum,
as supplemented and amended by the written communications listed on Annex A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company intends to use the proceeds of the
offering of the Securities to (i)&nbsp;repay a portion of the outstanding loans under its Credit Agreement, dated August&nbsp;30, 2019
among the Company, as borrower, the guarantors party thereto, each lender from time to time party thereto, and Wells Fargo Bank, N.A.
as administrative agent, and pay related fees and expenses and (ii)&nbsp;for general corporate purposes (collectively, the &ldquo;<U>Transactions</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchase
and Resale of the Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company agrees to issue and sell the Securities to the several Initial Purchasers as provided in this Agreement, and each Initial Purchaser,
on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees,
severally and not jointly, to purchase from the Company the respective principal amount of Securities set forth opposite such Initial
Purchaser&rsquo;s name in Schedule 1 hereto at a price equal to 98.75% of the principal amount thereof plus accrued interest, if any,
from October&nbsp;8, 2021 to the Closing Date. The Company will not be obligated to deliver any of the Securities except upon payment
for all the Securities to be purchased as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt; background-color: white">The
Initial Purchasers have advised the Company that the Initial Purchasers intend to offer the Securities for resale on the terms set forth
in the Time of Sale Information and will deliver a copy of the Time of Sale Information and the Offering Memorandum to each U.S. person
to whom it initially resells the Securities. Each Initial Purchaser, severally and not jointly, represents, warrants, and agrees tha</FONT><FONT STYLE="font-size: 10pt">t:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">it
is a qualified institutional buyer within the meaning of Rule&nbsp;144A under the Securities Act (a &ldquo;<U>QIB</U>&rdquo;) and an accredited
investor within the meaning of Rule&nbsp;501(a)&nbsp;of Regulation D under the Securities Act (&ldquo;<U>Regulation D</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">it
has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities by means of any form
of general solicitation or general advertising within the meaning of Rule&nbsp;502(c)&nbsp;of Regulation D or in any manner involving
a public offering within the meaning of Section&nbsp;4(a)(2)&nbsp;of the Securities Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">neither
it nor any of its affiliates participating in the offering of the Securities have solicited offers for, or offered or sold, and will not
solicit offers for, or offer or sell, the Securities as part of their initial offering except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(A)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
persons whom it or such affiliate reasonably believes to be QIBs in transactions pursuant to Rule&nbsp;144A under the Securities Act (&ldquo;<U>Rule&nbsp;144A</U>&rdquo;)
and in connection with each such sale, it or such affiliate has taken or will take reasonable steps to ensure that the purchaser of the
Securities is aware that such sale is being made in reliance on Rule&nbsp;144A; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(B)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">in
accordance with the restrictions set forth in Annex C hereto<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Initial Purchaser acknowledges and agrees that the Company and, for purposes of the &ldquo;no registration&rdquo; opinions to be delivered
to the Initial Purchasers pursuant to Sections 6(f)&nbsp;and 6(g), counsel for the Company and counsel for the Initial Purchasers, respectively,
may rely upon the accuracy of the representations and warranties of the Initial Purchasers, and compliance by the Initial Purchasers with
their agreements, contained in paragraph (b)&nbsp;above (including Annex C hereto), and each Initial Purchaser hereby consents to such
reliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company acknowledges and agrees that the Initial Purchasers may offer and sell Securities to or through any affiliate of an Initial Purchaser
and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser<FONT STYLE="background-color: white">;
<U>provided</U> that such offers and sales shall be made in accordance with the provisions of this Agreement</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
for and delivery of the Securities will be made at the offices of Latham&nbsp;&amp; Watkins LLP, 1271 Avenue of the Americas, New York,
New York, at 10:00 A.M., New York City time, on October&nbsp;8, 2021 (unless postponed in accordance with the provisions of Section&nbsp;10
hereof), or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representative
and the Company may agree upon in writing. The time and date of such payment and delivery is referred to herein as the &ldquo;<U>Closing
Date</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
for the Securities shall be made by wire transfer in immediately available funds to the account(s)&nbsp;specified by the Company to the
Representative against delivery to the nominee of The Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;), for the account of the Initial
Purchasers, of one or more global notes representing the Securities (collectively, the &ldquo;<U>Global Note</U>&rdquo;), with any transfer
taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Note will be made available for inspection
by the Representative not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company and the Guarantors acknowledge and agree that each Initial Purchaser is acting solely in the capacity of an arm&rsquo;s length
contractual counterparty to the Company and the Guarantors with respect to the offering of Securities contemplated hereby (including in
connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company,
the Guarantors or any other person. Additionally, neither the Representative nor any other Initial Purchaser is advising the Company,
the Guarantors or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company
and the Guarantors shall consult with their own advisors concerning such matters and shall be responsible for making their own independent
investigation and appraisal of the transactions contemplated hereby, and the Initial Purchasers shall have no responsibility or liability
to the Company or the Guarantors with respect thereto. Any review by the Representative or any Initial Purchaser of the Company, the Guarantors,
and the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the
Representative or such Initial Purchaser, as the case may be, and shall not be on behalf of the Company, the Guarantors or any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company and the Guarantors</U>. The Company and the Guarantors jointly and severally represent and warrant to each
Initial Purchaser that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Preliminary
Offering Memorandum, Time of Sale Information and Offering Memorandum.</I> The Preliminary Offering Memorandum, as of its date, did not,
the Time of Sale Information, at the Time of Sale, did not, and at the Closing Date, will not, and the Offering Memorandum, in the form
first used by the Initial Purchasers to confirm sales of the Securities and as of the Closing Date, will not, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company and the Guarantors make no representation or warranty with
respect to any statements or omissions made in reliance upon and in conformity with information furnished to the Company relating to any
Initial Purchaser in writing by an Initial Purchaser through the Representative expressly for use in the Preliminary Offering Memorandum,
the Time of Sale Information or the Offering Memorandum <FONT STYLE="background-color: white">or any amendment or supplement thereto</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Additional
Written Communications</I>. The Company and the Guarantors (including their agents and representatives, other than the Initial Purchasers
in their capacity as such) have not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize,
approve or refer to any written communication that constitutes an offer to sell or solicitation of an offer to buy the Securities (each
such communication by the Company and the Guarantors or their agents and representatives (other than a communication referred to in clauses
(i)&nbsp;and (ii)&nbsp;below and the documents listed in Annex A hereto) an &ldquo;<U>Issuer Written Communication</U>&rdquo;) other than
(i)&nbsp;the Preliminary Offering Memorandum, (ii)&nbsp;the Offering Memorandum, (iii)&nbsp;the documents listed on Annex A hereto, including
a term sheet substantially in the form of Annex B hereto, which constitute part of the Time of Sale Information, and (iv)&nbsp;any electronic
road show or other written communications, in each case, used in accordance with Section&nbsp;4(c)&nbsp;hereof. Each such Issuer Written
Communication, when taken together with the Time of Sale Information at the Time of Sale, did not, and at the Closing Date will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and the Guarantors make no representation
or warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance upon and in <FONT STYLE="background-color: white">conformity
with information furnished to the Company in writing by an Initial Purchaser through the Representative expressly for use in any Issuer
Written </FONT>Communication, the Time of Sale Information or the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Financial
Statements.</I> The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included
in each of the Time of Sale Information and the Offering Memorandum present fairly in all material respects the financial position of
the Company and its subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for
the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&ldquo;GAAP&rdquo;)
applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited, interim historical financial statements
subject to normal year-end adjustments and which do not contain certain footnotes as permitted by the applicable rules&nbsp;of the Securities
and Exchange Commission (the &ldquo;Commission&rdquo;), and any supporting schedules included in each of the Preliminary Offering Memorandum,
the Time of Sale Information and the Offering Memorandum; the other financial information of the Company and its consolidated subsidiaries
included in each of the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum has been derived from
the accounting records of the Company and its subsidiaries and presents fairly in all material respects the information shown thereby.
All &ldquo;non-GAAP financial measures&rdquo; (as such term is defined in the rules&nbsp;and regulations of the Commission) included in
each of the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum comply with Regulation G under the
Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable, in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Change.</I> Except as disclosed in the Time of Sale Information and the Offering Memorandum, since the date of the most
recent financial statements of the Company included in each of the Time of Sale Information and the Offering Memorandum (exclusive of
any amendment or supplement thereto) (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of
Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing
equity incentive plans described in, the Time of Sale Information and the Offering Memorandum), short-term debt or long-term debt of the
Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company
on any class of capital stock, or any material adverse change, or any development that could reasonably be expected to result in a material
adverse change, in or affecting the business, properties, management, financial position, results of operations or prospects of the Company
and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement
(whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred
any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither
the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its
subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Organization
and Good Standing.</I> The Company and each of its &ldquo;significant subsidiaries&rdquo; (as such term is defined in Rule&nbsp;1-02 of
Regulation S-X) have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions
of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or
lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary
to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so
qualified, in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect
on the business, properties, management, financial position, results of operations of the Company and its subsidiaries taken as a whole
or on the performance by the Company and the Guarantors of their obligations under this Agreement, the Securities and the Guarantees,
as applicable (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Capitalization.</I>
The Company has the capitalization as set forth in each of the Time of Sale Information and the Offering Memorandum under the heading
 &ldquo;Capitalization&rdquo;; and all the outstanding shares of capital stock or other equity interests of each significant subsidiary
of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly
by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim
of any third party (collectively, &ldquo;<U>Liens</U>&rdquo;), except for Liens pursuant to the Existing Indebtedness (as defined below),
which will be fully repaid and terminated on the Closing Date, as described in each of the Time of Sale Information and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Due
Authorization.</I> The Company and each of the Guarantors have full right, power and authority to execute and deliver this Agreement,
the Securities (solely in the case of the Company), the Indenture (including each Guarantee set forth therein) and the credit agreement
governing the new senior secured credit facilities (the &ldquo;<U>New Credit Agreement</U>&rdquo;) (collectively, the &ldquo;<U>Transaction
Documents</U>&rdquo;), and to perform their respective obligations hereunder and thereunder; and all action required to be taken for the
due and proper authorization, execution and delivery of each of the Transaction Documents and the consummation of the transactions contemplated
thereby has been duly and validly taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>The
Indenture</I>. The Indenture has been duly authorized by the Company and each of the Guarantors and on the Closing Date will be duly executed
and delivered by the Company and each of the Guarantors and, when duly executed and delivered in accordance with its terms by each of
the parties thereto, will constitute a valid and legally binding agreement of the Company and each of the Guarantors enforceable against
the Company and each of the Guarantors in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency or similar laws affecting the enforcement of creditors&rsquo; rights generally or by equitable principles relating to enforceability
(collectively, the &ldquo;<U>Enforceability Exceptions</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Purchase
Agreement. </I> This Agreement has been duly authorized, executed and delivered by the Company and each of the Guarantors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>The
Securities and the Guarantees</I>. The Securities have been duly authorized by the Company and, when duly executed, authenticated, issued
and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute
valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms, subject to the Enforceability
Exceptions, and will be entitled to the benefits of the Indenture; and the Guarantees have been duly authorized by each of the Guarantors
and, when the Securities have been duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided
herein, will be valid and legally binding obligations of each of the Guarantors, enforceable against each of the Guarantors in accordance
with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Descriptions
of the Transaction Documents</I>. Each Transaction Document conforms in all material respects to the description thereof contained in
each of the Time of Sale Information and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in
violation of any law or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory
authority having jurisdiction over the Company or any of its subsidiaries, except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above,
for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Conflicts</I>. The execution, delivery and performance by the Company and each of the Guarantors of each of the Transaction Documents
to which each is a party, the issuance and sale of the Securities by the Company and the issuance of the Guarantees by the Guarantors
and compliance by the Company and each of the Guarantors with the terms thereof and the consummation of the transactions contemplated
by the Transaction Documents will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of,
or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of
any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or
by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries
is subject (other than any lien, charge or encumbrance created or imposed pursuant to the collateral documents relating to the New Credit
Agreement, if any), (ii)&nbsp;result in any violation of the provisions of the charter or by-laws or similar organizational documents
of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation by the Company or any of its subsidiaries of any law or
statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority, except, (A)&nbsp;in
the case of clauses (i)&nbsp;and (iii)&nbsp;above, for any such conflict, breach, violation, default, lien, charge or encumbrance that
would not, individually or in the aggregate, have a Material Adverse Effect and (B)&nbsp;in the case of clause (i)&nbsp;above after giving
effect to the repayment and termination of the Company&rsquo;s existing senior secured credit facility (the &ldquo;<U>Existing Indebtedness</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Consents Required</I>. No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required for the execution, delivery and performance by the Company and each of the Guarantors
of each of the Transaction Documents to which each is a party, the issuance and sale of the Securities and the issuance of the Guarantees
and compliance by the Company and each of the Guarantors with the terms thereof and the consummation of the transactions contemplated
by the Transaction Documents, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be
required under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Legal
Proceedings.</I> Except as described in each of the Time of Sale Information and the Offering Memorandum, there are no legal, governmental
or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is a party or to which
any property of the Company or any of its subsidiaries is the subject that, individually or in the aggregate, could reasonably be expected
to have a Material Adverse Effect; and, to the knowledge of the Company and each of the Guarantors, no such investigations, actions, suits
or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened by others and there are no current
or pending legal, governmental or regulatory actions, suits or proceedings that are required under the Securities Act to be described
in each of the Time of Sale Information and the Offering Memorandum that are not so described therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Independent
Accountants.</I> PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company and its subsidiaries is an
independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules&nbsp;and regulations
adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Title
to Real and Personal Property.</I> The Company and its subsidiaries have good and marketable title in fee simple (in the case of real
property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are
material to the business of the Company and its subsidiaries, taken as a whole, in each case free and clear of all liens, encumbrances,
claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to
be made of such property by the Company and its subsidiaries or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Intellectual
Property.</I> Except as could not reasonably be expected to have a Material Adverse Effect or as disclosed in the Time of Sale Information
or the Offering Memorandum, (i)&nbsp;the Company and its subsidiaries own or possess adequate rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the
conduct of their business, and the conduct of their business will not conflict in any material respect with any such rights of others.
The Company and its subsidiaries have not received any written notice of any claim of infringement, misappropriation or conflict with
any such rights of others in connection with its patents, patent rights, licenses, inventions, trademarks, service marks, trade names,
copyrights and know-how, which could reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Cybersecurity;
Data Protection</I>. The Company&rsquo;s and its subsidiaries&rsquo; information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) are reasonably believed
by the Company to be adequate in all material respects for, and operate and perform in all material respects as required in connection
with, the operation of the business of the Company and its subsidiaries as currently conducted and, to the Company&rsquo;s knowledge,
are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its
subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect
their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data reasonably
consistent with industry standards and practices, or as required by applicable regulatory standards (and including all personal, personally
identifiable, sensitive, confidential or regulated data) (&ldquo;<U>IT Data</U>&rdquo;) and, to the knowledge of the Company there have
been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without
material cost or liability. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all
judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory authority and internal policies
and contractual obligations relating to the privacy and security of IT Systems and IT Data and to the protection of such IT Systems and
IT Data from unauthorized use, access, misappropriation or modification, except for such failures as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Data
Privacy and Security Laws</I>. Except as could not reasonably be expected to have a Material Adverse Effect or as disclosed in the Time
of Sale Information and the Offering Memorandum, the Company and its subsidiaries are, and since the Company&rsquo;s inception have been,
in compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation the Health
Insurance Portability and Accountability Act of 1996 (&ldquo;<U>HIPAA</U>&rdquo;) as amended by the Health Information Technology for
Economic and Clinical Health Act (the &ldquo;<U>HITECH Act</U>&rdquo;) (collectively, the &ldquo;<U>Privacy Laws</U>&rdquo;). To ensure
compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply in all material respects with, and take appropriate
steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &ldquo;Policies&rdquo;). &ldquo;Personal
Data&rdquo; means (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security
number or tax identification number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer
or account number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal
Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; and (iv)&nbsp;any other piece of information
that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related
to an identified person&rsquo;s health or sexual orientation. Except as could not reasonably be expected to have a Material Adverse Effect
or as disclosed in the Time of Sale Information and the Offering Memorandum, the Company and its subsidiaries have at all times made all
disclosures to users or customers required by applicable laws and regulatory rules&nbsp;or requirements, and none of such disclosures
made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory
rules&nbsp;or requirements. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect,
neither the Company nor any of its subsidiaries: (i)&nbsp;has received notice of any actual or potential liability under or relating to,
or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be
expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation
or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Complaints</I>. There is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against the
Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&rsquo;s use of the products
or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained
therein (&ldquo;<U>HHS</U>&rdquo;), or any similar authority in any jurisdiction other than the Unites States or any other governmental
entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company or its subsidiaries, except as
would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and, to the knowledge of the Company,
no such complaint, audit, proceeding, investigation or claim is threatened, except as could not reasonably be expected, individually or
in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Investment
Company Act.</I> Neither the Company nor any of the Guarantors is, or after giving effect to the offering and sale of the Securities by
the Company pursuant to this Agreement and the application of the proceeds thereof received by the Company as described in each of the
Time of Sale Information and the Offering Memorandum, none of them will be, an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended, and the rules&nbsp;and regulations
of the Commission thereunder (collectively, the &ldquo;<U>Investment Company Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Taxes.</I>
The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or
filed through the date hereof except for taxes being contested in good faith and for which reserves in accordance with GAAP have been
taken; and except as otherwise disclosed in each of the Time of Sale Information and the Offering Memorandum, there is no material tax
deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their
respective properties or assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Licenses
and Permits.</I> The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and
have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that
are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in
each of the Time of Sale Information and the Offering Memorandum, except where the failure to possess or make the same would not, individually
or in the aggregate, have a Material Adverse Effect; and except as described in the Time of Sale Information and the Offering Memorandum,
neither the Company nor any of its subsidiaries has received written notice of any revocation or modification of any such license, certificate,
permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in
the ordinary course, except in each case as would not reasonably be expected to have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no party granting any such licenses, certificates, permits and other authorizations has taken any action to limit, suspend
or revoke the same in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge
of the Company and each of the Guarantors, is contemplated or threatened and neither the Company nor any Guarantor is aware of any existing
or imminent labor disturbance by, or dispute with, the employees of any of the Company&rsquo;s or any of the Company&rsquo;s subsidiaries&rsquo;
principal suppliers, contractors or customers, except as would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Certain
Environmental Matters</I>. <FONT STYLE="background-color: white">(i)&nbsp;The Company and its subsidiaries (v)&nbsp;are in compliance
with all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and
the common law relating to pollution or the protection of human health or safety, the environment or natural resources, including those
relating to the generation, storage, treatment, use, handling, transportation, Release or threat of Release of Hazardous Materials (collectively,
 &ldquo;<U>Environmental Laws</U>&rdquo;), (w)&nbsp;have received and are in compliance with all permits, licenses, certificates or other
authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, (x)&nbsp;have
not received notice of any actual or potential liability under or relating to, or any actual or potential violation of, any Environmental
Laws, including for the investigation or remediation of any Release or threat of Release of Hazardous Materials, and have no knowledge
of any event or condition that would reasonably be expected to result in any such notice, (y)&nbsp;are not conducting or paying for, in
whole or in part, any investigation, remediation or other corrective action pursuant to any Environmental Law at any location, and (z)&nbsp;are
not a party to any order, decree or agreement that imposes any obligation or liability under any Environmental Law and (ii)&nbsp;there
are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of
each of (i)&nbsp;and (ii)&nbsp;above, for any such matter, as would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Time of Sale Information and the Offering Memorandum, (x)&nbsp;there
is no proceeding that is pending or, to the knowledge of the Company, contemplated against the Company or any of its subsidiaries under
any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed
no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues
regarding the Company&rsquo;s or its subsidiaries&rsquo; compliance with Environmental Laws, or liabilities or other obligations under
Environmental Laws, including the Release or threat of Release of Hazardous Materials, that could reasonably be expected to have a Material
Adverse Effect, and (z)&nbsp;none of the Company or any of its subsidiaries anticipates material capital expenditures relating to any
Environmental Laws.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Hazardous
Materials</I>. There has been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous
Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries,
any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably
be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or
any of its subsidiaries or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner
or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation
or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &ldquo;<U>Hazardous
Materials</U>&rdquo; means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof,
in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids,
asbestos and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can
give rise to liability under any Environmental Law. &ldquo;<U>Release</U>&rdquo; means any spilling, leaking, seepage, pumping, pouring,
emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through
the environment, or in, into from or through any building or structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Compliance
with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security
Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;), for which the Company or any member of its &ldquo;Controlled Group&rdquo; (defined
as any organization which is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of the Code) would
have any liability and which is established or maintained by the Company for the benefit of its employees (each, a &ldquo;<U>Plan</U>&rdquo;)
has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations,
including but not limited to ERISA and the Code, except for noncompliance that could not reasonably be expected to result in material
liability to the Company or its subsidiaries; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or
Section&nbsp;4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative
exemption that could reasonably be expected to result in a material liability to the Company or its subsidiaries; (iii)&nbsp;for each
Plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, the minimum funding standard
of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, as applicable, has been satisfied (without taking into account any waiver
thereof or extension of any amortization period) and is reasonably expected to be satisfied in the future (without taking into account
any waiver thereof or extension of any amortization period); (iv)&nbsp;to the extent applicable to a Plan, the fair market value of the
assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund
such Plan); (v)&nbsp;no &ldquo;reportable event&rdquo; (within the meaning of Section&nbsp;4043(c)&nbsp;of ERISA) has occurred or is reasonably
expected to occur that either has resulted, or could reasonably be expected to result, in material liability to the Company or its subsidiaries;
(vi)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under
Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect
of a Plan (including a &ldquo;multiemployer plan&rdquo;, within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA); and (vii)&nbsp;there
is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation
or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably be expected to result
in material liability to the Company or its subsidiaries. None of the following events has occurred or is reasonably likely to occur:
(x)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its subsidiaries
in the current fiscal year of the Company and its subsidiaries compared to the amount of such contributions made in the Company and its
subsidiaries&rsquo; most recently completed fiscal year; or (y)&nbsp;a material increase in the Company and its subsidiaries&rsquo; &ldquo;accumulated
post-retirement benefit obligations&rdquo; (within the meaning of Statement of Financial Accounting Standards 106) compared to the amount
of such obligations in the Company and its subsidiaries&rsquo; most recently completed fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Disclosure
Controls</I>. Except as disclosed in the Time of Sale Information and the Offering Memorandum, the Company and its subsidiaries maintain
an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that
is designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms,
including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&rsquo;s management
as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of
its disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Accounting
Controls.</I> Except as disclosed in each of the Time of Sale Information and the Offering Memorandum, the Company and its subsidiaries
maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act)
that are designed to comply with the requirements of 13a-15(f)&nbsp;of the Exchange Act and have been designed by, or under the supervision
of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP. Except as disclosed in each of the Time of Sale Information and the Offering Memorandum, the Company and its subsidiaries maintain
internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management's
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Based on the Company&rsquo;s most recent evaluation of its
internal controls over financial reporting pursuant to Rule&nbsp;13a-15(c)&nbsp;of the Exchange Act; there are no material weaknesses
in the Company&rsquo;s internal controls, except as disclosed in each of the Time of Sale Information and the Offering Memorandum. The
Company&rsquo;s auditors and the Audit and Risk Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely
affected or are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal controls over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Insurance.
 &nbsp;</I>The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including
business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes
are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries
has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or
necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be
necessary to continue its business except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Unlawful Payments.</I> &nbsp;Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the Company or any of
its subsidiaries nor, to the knowledge of the Company and each of the Guarantors, any agent or affiliate of the Company or any of its
subsidiaries (in their capacities as such) has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization
of any direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee , including
of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for
or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated
or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under
the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv)&nbsp;made, offered,
agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate,
payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted,
maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with
all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Compliance
with Anti-Money Laundering Laws</I>. &nbsp;The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental or regulatory agency (collectively, the &ldquo;<U>Anti-Money Laundering Laws</U>&rdquo;), and no action,
suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company
or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company or any of the
Guarantors, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Conflicts with Sanctions Laws</I>. &nbsp;Neither the Company nor any of its subsidiaries, directors or officers, nor, to the knowledge of the
Company or any of the Guarantors, any employee, agent or affiliate of the Company or any of its subsidiaries (in their capacities as such)
is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation,
the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<U>OFAC</U>&rdquo;) or the U.S. Department of State
and including, without limitation, the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;),
the United Nations Security Council (&ldquo;<U>UNSC</U>&rdquo;), the European Union, Her Majesty&rsquo;s Treasury (&ldquo;<U>HMT</U>&rdquo;),
or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), nor is the Company, any of its subsidiaries or any
of the Guarantors located, organized or resident in a country or territory that is the subject or the target of Sanctions, including,
without limitation, Crimea, Cuba,&nbsp;Iran, North Korea, Syria and Crimea (each, a &ldquo;<U>Sanctioned Country</U>&rdquo;); and the
Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to
fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as initial purchaser, underwriter, advisor, investor or
otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly
engaged, and will not engage, in any dealings or transactions with any person that at the time of the dealing or transaction is or was
the subject or the target of Sanctions or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Solvency.</I>
 &nbsp;On and immediately after the Closing Date, the Company and each Guarantor (after giving effect to the issuance and sale of the Securities,
the issuance of the Guarantees, the Refinancing and the other transactions related thereto as described in each of the Time of Sale Information
and the Offering Memorandum) will be Solvent. As used in this paragraph, the term &ldquo;<U>Solvent</U>&rdquo; means, with respect to
a particular date and entity, that on such date (i)&nbsp;the fair value (and present fair saleable value) of the assets of such entity
is not less than the total amount required to pay the probable liability of such entity on its total existing debts and liabilities (including
contingent liabilities) as they become absolute and matured; (ii)&nbsp;such entity is able to realize upon its assets and pay its debts
and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business; (iii)&nbsp;assuming
consummation of the issuance and sale of the Securities and the issuance of the Guarantees as contemplated by this Agreement, and the
consummation of the Refinancing, in each case, as contemplated by the Time of Sale Information and the Offering Memorandum, such entity
does not have, intend to incur or believe that it will incur debts or liabilities beyond its ability to pay as such debts and liabilities
mature; (iv)&nbsp;such entity is not engaged in any business or transaction, and does not propose to engage in any business or transaction,
for which its property would constitute unreasonably small capital; and (v)&nbsp;such entity is not a defendant in any civil action that
would result in a judgment that such entity is or would become unable to satisfy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Restrictions on Subsidiaries</I>. &nbsp;No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or
other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on
such subsidiary&rsquo;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary
from the Company or from transferring any of such subsidiary&rsquo;s properties or assets to the Company or any other subsidiary of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Broker&rsquo;s Fees.</I> &nbsp;Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any
person (other than the Transaction Documents) that would give rise to a valid claim against any of them or any Initial Purchaser for a
brokerage commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Securities by the Company pursuant
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Rule&nbsp;144A
Eligibility.</I> &nbsp;On the Closing Date, the Securities will not be of the same class as securities listed on a national securities exchange
registered under Section&nbsp;6 of the Exchange Act or quoted in an automated inter-dealer quotation system; and each of the Preliminary
Offering Memorandum and the Offering Memorandum, as of its respective date, contains or will contain all the information that, if requested
by a prospective purchaser of the Securities, would be required to be provided to such prospective purchaser pursuant to Rule&nbsp;144A(d)(4)&nbsp;under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Integration.</I> &nbsp;Neither the Company nor any of its affiliates (as defined in Rule&nbsp;501(b)&nbsp;of Regulation D) has, directly or
through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in
the Securities Act), that is or will be integrated with the sale of the Securities in a manner that would require registration of the
Securities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
General Solicitation or Directed Selling Efforts.</I> &nbsp;None of the Company or any of its affiliates or any other person acting on its or
their behalf (other than the Initial Purchasers and certain of their affiliates, as to which no representation is made) has (i)&nbsp;solicited
offers for, or offered or sold, the Securities by means of any form of general solicitation or general advertising within the meaning
of Rule&nbsp;502(c)&nbsp;of Regulation D or in any manner involving a public offering within the meaning of Section&nbsp;4(a)(2)&nbsp;of
the Securities Act or (ii)&nbsp;engaged in any directed selling efforts within the meaning of Regulation S under the Securities Act (&ldquo;<U>Regulation
S</U>&rdquo;), and all such persons have complied with the offering restrictions requirement of Regulation S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Securities
Law Exemptions.</I> &nbsp;Assuming the accuracy of the representations and warranties of the Initial Purchasers contained in Section&nbsp;2(b)&nbsp;(including
Annex C hereto) and their compliance with their agreements set forth therein, it is not necessary, in connection with the issuance and
sale of the Securities to the Initial Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the
manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, to register the Securities under the
Securities Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Stabilization.</I> &nbsp;Neither the Company nor any of the Guarantors has taken, directly or indirectly, any action designed to or that could
reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(qq)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Forward-Looking
Statements.</I> &nbsp;No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) included in any of the Time of Sale Information or the Offering Memorandum has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(rr)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Statistical
and Market Data.</I> &nbsp;Nothing has come to the attention of the Company or any Guarantor that has caused the Company or such Guarantor to
believe that the statistical and market-related data included in each of the Time of Sale Information and the Offering Memorandum is not
based on or derived from sources that are reliable and accurate in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ss)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Sarbanes-Oxley
Act</I>. &nbsp;There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules&nbsp;and regulations promulgated in
connection therewith (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), including Section&nbsp;402 related to loans and Sections 302 and 906
related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(tt)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Margin
Rules</I>. &nbsp;Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described
in each of the Time of Sale Information and the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the
Federal Reserve System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Further
Agreements of the Company and the Guarantors</U>. &nbsp;The Company and the Guarantors jointly and severally covenant and agree with each Initial
Purchaser that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Delivery
of Copies.</I> &nbsp;The Company will deliver, without charge, to the Initial Purchasers, if requested, as many copies of the Preliminary Offering
Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments
and supplements thereto and documents incorporated by reference therein and in each Issuer Written Communication) as the Representative
may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Offering
Memorandum, Amendments or Supplements.</I> &nbsp;Before finalizing the Offering Memorandum or making or distributing any amendment or supplement
to any of the Time of Sale Information or the Offering Memorandum, the Company will furnish to the Representative and counsel for the
Initial Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement for review, and will not distribute any
such proposed Offering Memorandum, amendment or supplement to which the Representative reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Additional
Written Communications.</I> &nbsp;Before making, preparing, using, authorizing, approving or referring to any Issuer Written Communication,
the Company and the Guarantors will furnish to the Representative and counsel for the Initial Purchasers a copy of such written communication
for review and will not make, prepare, use, authorize, approve or refer to any such written communication to which the Representative
reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notice
to the Representative.</I> &nbsp;The Company will advise the Representative promptly, and confirm such advice in writing, (i)&nbsp;of the issuance
by any governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Information, any
Issuer Written Communication or the Offering Memorandum or the initiation or threatening of any proceeding for that purpose; (ii)&nbsp;of
the occurrence of any event at any time prior to the completion of the initial offering of the Securities as a result of which any of
the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum as then amended or supplemented would include
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances existing when such Time of Sale Information,&nbsp;Issuer Written Communication or the Offering Memorandum is delivered
to a purchaser, not misleading; and (iii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification
of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the
Company will use its reasonable best efforts to prevent the issuance of any such order preventing or suspending the use of any of the
Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the Securities
and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Time
of Sale Information. &nbsp;</I>If at any time prior to the Closing Date (i)&nbsp;any event shall occur or condition shall exist as a result
of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company
will promptly notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (b)&nbsp;above, furnish to the Initial
Purchasers such amendments or supplements to the Time of Sale Information as may be necessary so that the statements in any of the Time
of Sale Information as so amended or supplemented will not, in the light of the circumstances under which they were made, be misleading
or so that any of the Time of Sale Information will comply with law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Ongoing
Compliance.</I> &nbsp;If at any time prior to the completion of the initial offering of the Securities (i)&nbsp;any event shall occur or condition
shall exist as a result of which the Offering Memorandum as then amended or supplemented would include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing
when the Offering Memorandum is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Offering
Memorandum to comply with law, the Company will as promptly as practicable notify the Initial Purchasers thereof and forthwith prepare
and, subject to paragraph (b)&nbsp;above, furnish to the Initial Purchasers such amendments or supplements to the Offering Memorandum
as may be necessary so that the statements in the Offering Memorandum as so amended or supplemented will not, in the light of the circumstances
existing when the Offering Memorandum is delivered to a purchaser, be misleading or so that the Offering Memorandum will comply with law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Blue
Sky Compliance.</I> &nbsp;The Company will qualify the Securities for offer and sale by the Initial Purchasers under the securities or Blue
Sky laws of such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long
as required for the offering and resale of the Securities; <U>provided</U> that neither the Company nor any of the Guarantors shall be
required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would
not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject
itself to taxation in any such jurisdiction if it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Clear
Market.</I> &nbsp;During the period from the date hereof through and including the date that is 90 days after the date hereof, the Company and
each of the Guarantors will not, without the prior written consent of the Representative, offer, sell, contract to sell or otherwise dispose
of any debt securities issued or guaranteed by the Company or any of the Guarantors and having a tenor of more than one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Use
of Proceeds.</I> &nbsp;The Company will apply the net proceeds from the sale of the Securities as described in each of the Time of Sale Information
and the Offering Memorandum under the heading &ldquo;Use of proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Supplying
Information.</I> &nbsp;While the Securities remain outstanding and are &ldquo;restricted securities&rdquo; within the meaning of Rule&nbsp;144(a)(3)&nbsp;under
the Securities Act, the Company and each of the Guarantors will, during any period in which the Company is not subject to and in compliance
with Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act, furnish to holders of the Securities and prospective purchasers of the Securities
designated by such holders, upon the request of such holders or such prospective purchasers, the information required to be delivered
pursuant to Rule&nbsp;144A(d)(4)&nbsp;under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>DTC.</I>
 &nbsp;The Company will reasonably cooperate with the Initial Purchasers in arranging for the Securities to be eligible for clearance and settlement
through DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Resales by the Company.</I> &nbsp;The Company will not, and will not permit any of its affiliates (as defined in Rule&nbsp;144 under the Securities
Act) to, resell any of the Securities that have been acquired by any of them, except for Securities purchased by the Company or any of
its affiliates and resold in a transaction registered under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Integration.</I> &nbsp;Neither the Company nor any of its affiliates (as defined in Rule&nbsp;501(b)&nbsp;of Regulation D) will, directly or
through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any security (as defined in the Securities
Act), that is or will be integrated with the sale of the Securities in a manner that would require registration of the Securities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
General Solicitation or Directed Selling Efforts.</I> &nbsp;None of the Company or any of its affiliates or any other person acting on its or
their behalf (other than the Initial Purchasers, as to which no covenant is given) will (i)&nbsp;solicit offers for, or offer or sell,
the Securities by means of any form of general solicitation or general advertising within the meaning of Rule&nbsp;502(c)&nbsp;of Regulation
D or in any manner involving a public offering within the meaning of Section&nbsp;4(a)(2)&nbsp;of the Securities Act or (ii)&nbsp;engage
in any directed selling efforts within the meaning of Regulation S, and all such persons will comply with the offering restrictions requirement
of Regulation S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Stabilization.</I> &nbsp;Neither the Company nor any of the Guarantors will take, directly or indirectly, any action designed to or that could
reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Agreements of the Initial Purchasers</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each Initial Purchaser
hereby represents and agrees that it has not and will not use, authorize use of, refer to, or participate in the planning for use of,
any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i)&nbsp;the
Preliminary Offering Memorandum and the Offering Memorandum, (ii)&nbsp;any written communication that contains either (a)&nbsp;no &ldquo;issuer
information&rdquo; (as defined in Rule&nbsp;433(h)(2)&nbsp;under the Securities Act) or (b)&nbsp;&ldquo;issuer information&rdquo; that
was included in the Time of Sale Information or the Offering Memorandum, (iii)&nbsp;any written communication listed on Annex A or prepared
pursuant to Section&nbsp;4(c)&nbsp;(including any electronic road show) above, (iv)&nbsp;any written communication prepared by such Initial
Purchaser and approved by the Company and the Representative in advance in writing or (v)&nbsp;any written communication relating to or
that contains the terms of the Securities and/or other information that was included in the Time of Sale Information or the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
of Initial Purchasers&rsquo; Obligations.</U> &nbsp;The obligation of each Initial Purchaser to purchase Securities on the Closing Date as provided
herein is subject to the performance by the Company and each of the Guarantors of their respective covenants and other obligations hereunder
and to the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Representations
and Warranties.</I> &nbsp;The representations and warranties of the Company and the Guarantors contained herein shall be true and correct on
the date hereof and on and as of the Closing Date; and the statements of the Company, the Guarantors and their respective officers made
in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Downgrade.</I> &nbsp;Subsequent to the earlier of (A)&nbsp;the Time of Sale and (B)&nbsp;the execution and delivery of this Agreement, (i)&nbsp;no
downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock issued or guaranteed
by the Company or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is
defined under Section&nbsp;3(a)(62) under the Exchange Act and (ii)&nbsp;no such organization shall have publicly announced that it has
under surveillance or review, or has changed its outlook with respect to, its rating of the Securities or of any other debt securities
or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive implications
of a possible upgrading).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Change.</I> &nbsp;No event or condition of a type described in Section&nbsp;3(d)&nbsp;hereof shall have occurred or shall exist,
which event or condition is not described in each of the Time of Sale Information (excluding any amendment or supplement thereto) and
the Offering Memorandum (excluding any amendment or supplement thereto) the effect of which in the judgment of the Representative makes
it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms and
in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Officer&rsquo;s
Certificate.</I> &nbsp;The Representative shall have received on and as of the Closing Date a certificate of an executive officer of the Company
reasonably satisfactory to the Representative (i)&nbsp;confirming that such officer has carefully reviewed the Time of Sale Information
and the Offering Memorandum and, to the knowledge of such officer, the representations of the Company and the Guarantors set forth in
Sections 3(a)&nbsp;and 3(b)&nbsp;hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the
Company and the Guarantors in this Agreement are true and correct and that the Company and the Guarantors have complied with all agreements
and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date and (iii)&nbsp;to the
effect set forth in paragraphs (b)&nbsp;and (c)&nbsp;above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Comfort
Letters.</I> &nbsp;On the date of this Agreement and on the Closing Date, PricewaterhouseCoopers LLP shall have furnished to the Representative,
at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Initial Purchasers, in form
and substance reasonably satisfactory to the Representative, containing statements and information of the type customarily included in
accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial information
contained in each of the Time of Sale Information and the Offering Memorandum; <U>provided</U> that the letter delivered on the Closing
Date shall use a &ldquo;cut-off&rdquo; date no more than three business days prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
and 10b-5 Statement of Counsel for the Company.</I> &nbsp;Willkie Farr&nbsp;&amp; Gallagher LLP, counsel for the Company, shall have furnished
to the Representative, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date and addressed
to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
and 10b-5 Statement of Counsel for the Initial Purchasers.</I> &nbsp;The Representative shall have received on and as of the Closing Date an
opinion and 10b-5 statement, addressed to the Initial Purchasers, of Latham&nbsp;&amp; Watkins LLP, counsel for the Initial Purchasers,
with respect to such matters as the Representative may reasonably request, and such counsel shall have received such documents and information
as they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
for Fort Effect Corp. </I>&nbsp;Lathrop GPM LLP, local counsel for Fort Effect Corp., shall have furnished to the Representative, at the request
of the Company, their written opinion, dated the Closing Date and addressed to the Initial Purchasers, in form and substance reasonably
satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Legal Impediment to Issuance</I>. &nbsp;No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted
or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance
or sale of the Securities by the Company pursuant to this Agreement or the issuance of the Guarantees; and no injunction or order of any
federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities
by the Company pursuant to this Agreement or the issuance of the Guarantees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Good
Standing</I>. &nbsp;The Representative shall have received on and as of a recent day prior to the Closing Date satisfactory evidence of the
good standing of the Company and the Guarantors in their respective jurisdictions of organization, in each case in writing or any standard
form of telecommunication from the appropriate governmental authorities of such jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>DTC.</I>
 &nbsp;The Securities shall be eligible for clearance and settlement through DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Indenture
and Securities</I>. &nbsp;The Indenture shall have been duly executed and delivered by a duly authorized officer of the Company, each of the
Guarantors and the Trustee, and the Securities shall have been duly executed and delivered by a duly authorized officer of the Company
and duly authenticated by the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Existing
Indebtedness</I>. &nbsp;The Representative shall have received evidence reasonably satisfactory to it that, substantially simultaneously with
the purchase of the Securities by the Initial Purchasers, all outstanding Existing Indebtedness, and all accrued and unpaid interest,
fees and other amounts owing thereunder, shall have been paid in full, all commitments to extend credit under the Existing Indebtedness
shall have terminated, and all liens securing obligations thereunder shall have been released.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>The
Refinancing</I>. &nbsp;Concurrently with or prior to the Closing Date, the Refinancing shall have been consummated in a manner consistent in
all material respects with the description thereof in the Time of Sale Information and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Additional
Documents.</I> &nbsp;On or prior to the Closing Date, the Company and the Guarantors shall have furnished to the Representative such further
certificates and documents as the Representative may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Initial Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Initial Purchasers.</I> &nbsp;The Company and each of the Guarantors jointly and severally agree to indemnify and hold harmless each
Initial Purchaser, its affiliates, directors and officers and each person, if any, who controls such Initial Purchaser within the meaning
of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages
and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any
suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are
based upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any
of the other Time of Sale Information, any Issuer Written Communication or the Offering Memorandum (or any amendment or supplement thereto)
or any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities
arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with any information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through
the Representative expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Company and the Guarantors.</I> &nbsp;Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company,
each of the Guarantors, each of their respective directors and officers and each person, if any, who controls the Company or any of the
Guarantors within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the
indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of,
or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with
any information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative
expressly for use in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication
or the Offering Memorandum (or any amendment or supplement thereto), it being understood and agreed that the only such information consists
of the fourth paragraph, the fourth and fifth sentences of the twelfth paragraph and the thirteenth and fourteenth paragraphs under the
heading &ldquo;Plan of Distribution&rdquo; in the Preliminary Offering Memorandum and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notice
and Procedures.</I> &nbsp;If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be
brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b)&nbsp;above,
such person (the &ldquo;<U>Indemnified Person</U>&rdquo;) shall promptly notify the person against whom such indemnification may be sought
(the &ldquo;Indemnifying Person&rdquo;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve
it from any liability that it may have under paragraph (a)&nbsp;or (b)&nbsp;above except to the extent that it has been materially prejudiced
(through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify
the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph
(a)&nbsp;or (b)&nbsp;above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified
the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall
not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any
others entitled to indemnification pursuant to this Section&nbsp;7 that the Indemnifying Person may designate in such proceeding and shall
pay the fees and expenses of such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to
such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees
and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified
Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel
reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be
legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the
named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person
and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.
It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel (not to exceed one
in each jurisdiction)) for all Indemnified Persons, and that all such reasonable and documented fees and expenses shall be paid or reimbursed
as they are incurred. Any such separate firm for any Initial Purchaser, its affiliates, directors and officers and any control persons
of such Initial Purchaser shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, the
Guarantors, their respective directors and officers and any control persons of the Company and the Guarantors shall be designated in writing
by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent,
but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified
Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at
any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses
of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without
its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request
and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date
of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any
pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have
been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified
Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or
on behalf of any Indemnified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Contribution.</I>
 &nbsp;If the indemnification provided for in paragraph (a)&nbsp;or (b)&nbsp;above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu
of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result
of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company and the Guarantors on the one hand and the Initial Purchasers on the other from the offering of the Securities or (ii)&nbsp;if
the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company and the Guarantors on the one hand and
the Initial Purchasers on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities,
as well as any other relevant equitable considerations. The relative benefits received by the Company and the Guarantors on the one hand
and the Initial Purchasers on the other shall be deemed to be in the same respective proportions as the net proceeds (before deducting
expenses) received by the Company from the sale of the Securities and the total discounts and commissions received by the Initial Purchasers
in connection therewith, as provided in this Agreement, bear to the aggregate offering price of the Securities. The relative fault of
the Company and the Guarantors on the one hand and the Initial Purchasers on the other shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or any Guarantor or by the Initial Purchasers and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Limitation
on Liability.</I> &nbsp;The Company, the Guarantors and the Initial Purchasers agree that it would not be just and equitable if contribution
pursuant to this Section&nbsp;7 were determined by <U>pro</U> <U>rata</U> allocation (even if the Initial Purchasers were treated as one entity
for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph
(d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred
to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred
by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this Section&nbsp;7, in no event
shall an Initial Purchaser be required to contribute any amount in excess of the amount by which the total discounts and commissions received
by such Initial Purchaser with respect to the offering of the Securities exceeds the amount of any damages that such Initial Purchaser
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers&rsquo; obligations to contribute pursuant
to this Section&nbsp;7 are several in proportion to their respective purchase obligations hereunder and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Non-Exclusive
Remedies.</I> &nbsp;The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies that may otherwise
be available to any Indemnified Person at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Effectiveness
of Agreement</U>. &nbsp;This Agreement shall become effective as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.
 &nbsp;This Agreement may be terminated in the absolute discretion of the Representative, by notice to the Company, if after the execution and
delivery of this Agreement and on or prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited
on the New York Stock Exchange or the Nasdaq Stock Market LLC; (ii)&nbsp;trading of any securities issued or guaranteed by the Company
or any of the Guarantors shall have been suspended on any exchange or in any over-the-counter market; (iii)&nbsp;a general moratorium
on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred
any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United
States, that, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to proceed with
the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information
and the Offering Memorandum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Defaulting
Initial Purchaser</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
on the Closing Date, any Initial Purchaser defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder,
the non-defaulting Initial Purchasers may in their discretion arrange for the purchase of such Securities by other persons satisfactory
to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Initial Purchaser, the non-defaulting
Initial Purchasers do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours
within which to procure other persons satisfactory to the non-defaulting Initial Purchasers to purchase such Securities on such terms.
If other persons become obligated or agree to purchase the Securities of a defaulting Initial Purchaser, either the non-defaulting Initial
Purchasers or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Initial Purchasers may be necessary in the Time of Sale Information, the Offering Memorandum
or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Time of Sale Information
or the Offering Memorandum that effects any such changes. As used in this Agreement, the term &ldquo;Initial Purchaser&rdquo; includes,
for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to
this Section&nbsp;10, purchases Securities that a defaulting Initial Purchaser agreed but failed to purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by
the non-defaulting Initial Purchasers and the Company as provided in paragraph (a)&nbsp;above, the aggregate principal amount of such
Securities that remains unpurchased does not exceed one-eleventh of the aggregate principal amount of all the Securities, then the Company
shall have the right to require each non-defaulting Initial Purchaser to purchase the principal amount of Securities that such Initial
Purchaser agreed to purchase hereunder plus such Initial Purchaser&rsquo;s <U>pro rata</U> share (based on the principal amount of Securities
that such Initial Purchaser agreed to purchase hereunder) of the Securities of such defaulting Initial Purchaser or Initial Purchasers
for which such arrangements have not been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by
the non-defaulting Initial Purchasers and the Company as provided in paragraph (a)&nbsp;above, the aggregate principal amount of such
Securities that remains unpurchased exceeds one-eleventh of the aggregate principal amount of all the Securities, or if the Company shall
not exercise the right described in paragraph (b)&nbsp;above, then this Agreement shall terminate without liability on the part of the
non-defaulting Initial Purchasers. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the
part of the Company or the Guarantors, except that the Company and each of the Guarantors will continue to be liable for the payment of
expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall
remain in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Nothing
contained herein shall relieve a defaulting Initial Purchaser of any liability it may have to the Company, the Guarantors or any non-defaulting
Initial Purchaser for damages caused by its default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
of Expenses</U><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company and each of the Guarantors
jointly and severally agree to pay or cause to be paid all costs and expenses incident to the performance of their respective obligations
hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of
the Securities and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation and printing of the Preliminary
Offering Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including any amendment
or supplement thereto) and the distribution thereof; (iii)&nbsp;the costs of reproducing and distributing each of the Transaction Documents;
(iv)&nbsp;the fees and expenses of the Company's and the Guarantors&rsquo; counsel and independent accountants; (v)&nbsp;the fees and
expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities
under the laws of such jurisdictions as the Representative may designate and the preparation, printing and distribution of a Blue Sky
Memorandum (including the related fees and expenses of counsel for the Initial Purchasers) (not to exceed $20,000 with respect to this
clause (v));&nbsp;(vi)&nbsp;any fees charged by rating agencies for rating the Securities; (vii)&nbsp;the fees and expenses of the Trustee
and any paying agent (including related fees and expenses of any counsel to such parties); (viii)&nbsp;all expenses and application fees
incurred in connection with the approval of the Securities for book-entry transfer by DTC and (ix)&nbsp;all expenses incurred by the Company
in connection with any &ldquo;road show&rdquo; presentation to potential investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
(i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii)&nbsp;the Company for any reason fails to tender the Securities
for delivery to the Initial Purchasers or (iii)&nbsp;the Initial Purchasers decline to purchase the Securities for any reason permitted
under this Agreement, the Company and each of the Guarantors jointly and severally agree to reimburse the Initial Purchasers for all out-of-pocket
costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Initial Purchasers in connection with
this Agreement and the offering contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Persons
Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Initial Purchaser
referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or
equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from
any Initial Purchaser shall be deemed to be a successor merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company, the Guarantors and the
Initial Purchasers contained in this Agreement or made by or on behalf of the Company, the Guarantors or the Initial Purchasers pursuant
to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall
remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company,
the Guarantors or the Initial Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &ldquo;<U>affiliate</U>&rdquo;
has the meaning set forth in Rule&nbsp;405 under the Securities Act; (b)&nbsp;the term &ldquo;<U>business day</U>&rdquo; means any day
other than a day on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term &ldquo;<U>subsidiary</U>&rdquo;
has the meaning set forth in Rule&nbsp;405 under the Securities Act; (d)&nbsp;the term &ldquo;<U>Exchange Act</U>&rdquo; collectively
means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission thereunder; (e)&nbsp;the term
 &ldquo;<U>written communication</U>&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act; and (f)&nbsp;the term
 &ldquo;<U>significant subsidiary</U>&rdquo; has the meaning set forth in Rule&nbsp;1-02 of Regulation S-X under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including
the Company, which information may include the name and address of their respective clients, as well as other information that will allow
the Initial Purchasers to properly identify their respective clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Authority
of the Representative.</I> Any action by the Initial Purchasers hereunder may be taken by J.P. Morgan Securities LLC on behalf of the
Initial Purchasers, and any such action taken by J.P. Morgan Securities LLC shall be binding upon the Initial Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notices.</I>
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Representative c/o J.P.
Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: 212-270-1063); Attention: Blake Sitka. Notices to the Company
and the Guarantors shall be given to them at HealthEquity,&nbsp;Inc., 15 West Scenic Pointe Drive, Draper, Utah 84020, (fax: (801) 727-1005),
Attention: Delano Ladd, Executive Vice President, General Counsel and Corporate Secretary, with a copy to (which shall not constitute
notice): Willkie Farr&nbsp;&amp; Gallagher LLP, 787 Seventh Avenue, New York, N.Y. 10019 (fax: (212) 728-8111), Attention: Matthew Haddad,&nbsp;Esq.
and Jeffrey S. Hochman,&nbsp;Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD><I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed
by and construed in accordance with the laws of the State of New York.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD><I>Submission to Jurisdiction</I>. The Company and each of the Guarantors hereby submit to the exclusive jurisdiction of the U.S.
federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby. The Company and each of the Guarantors waive any objection which it may now
or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of the Company and each of the Guarantors
agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company
and each Guarantor, as applicable, and may be enforced in any court to the jurisdiction of which Company and each Guarantor, as applicable,
is subject by a suit upon such judgment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD><I>Waiver of Jury Trial. </I>Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising
out of or relating to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD><I>Recognition of the U.S. Special Resolution Regimes</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;In the event that any Initial
Purchaser that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Initial
Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer
would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by
the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;In the event that any Initial
Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser becomes subject to a proceeding under a U.S. Special
Resolution Regime, Default Rights under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised
to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">As used in this Section&nbsp;16(f):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to
the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;Covered Entity&rdquo; means any
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(i)&nbsp;a &ldquo;covered entity&rdquo; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;Default Right&rdquo; has the meaning assigned to that
term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;U.S. Special Resolution Regime&rdquo; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street
Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD><I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD><I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD><I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect
the meaning or interpretation of, this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1in; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">If
the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HEALTHEQUITY,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tyson Murdock</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>Executive Vice President and <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAGEWORKS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tyson Murdock</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIKING ACQUISITION CORP.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ted Bloomberg</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FORT EFFECT CORP.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ E. Sohier Hall</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted: As of the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For itself and on behalf of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">several Initial Purchasers listed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">in Schedule 1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Blake Sitka</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Initial Purchaser</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Principal Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left">J.P. Morgan Securities LLC</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">220,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Wells Fargo Securities, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Truist Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">RBC Capital Markets, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Citizens Capital Markets,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">MUFG Securities Americas Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">BMO Capital Markets Corp.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Capital One Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fifth Third Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">KeyBanc Capital Markets Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">TD Securities (USA) LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Huntington Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Regions Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Bancroft Capital LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">500,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 5in">Schedule 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>WageWorks,&nbsp;Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Viking Acquisition Corp.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Fort Effect Corp.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ANNEX A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Additional Time of Sale Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Term sheet containing the terms
of the Securities, substantially in the form of Annex B.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ANNEX B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Pricing Term Sheet, dated September&nbsp;28,
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>to Preliminary Offering Memorandum dated September&nbsp;28,
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Strictly Confidential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HEALTHEQUITY,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This pricing term sheet is qualified in its entirety by reference to
the Preliminary Offering Memorandum (the &ldquo;Preliminary Offering Memorandum&rdquo;). The information in this pricing term sheet supplements
the Preliminary Offering Memorandum and updates and supersedes the information in the Preliminary Offering Memorandum to the extent it
is inconsistent with the information in the Preliminary Offering Memorandum. Terms used and not defined herein have the meanings assigned
in the Preliminary Offering Memorandum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The notes have not been registered under the Securities Act of 1933,
as amended, or the securities laws of any other jurisdiction. The notes may not be offered or sold in the United States or to U.S. persons
(as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act.
Accordingly, the notes are being offered only to (1)&nbsp;&ldquo;qualified institutional buyers&rdquo; as defined in Rule&nbsp;144A under
the Securities Act and (2)&nbsp;outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HealthEquity,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security description:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.500% Senior Notes due 2029</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144A/Reg S for life</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Size:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$500,000,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross proceeds:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$500,000,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2029</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coupon:&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.500%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue price:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% of face amount</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yield to maturity:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.500%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spread to Benchmark Treasury: </FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+312 basis points</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benchmark Treasury:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UST 1.625% due August&nbsp;15, 2029</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Payment Dates:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1 and April&nbsp;1, commencing April&nbsp;1, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rating*</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B3/B</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Clawback:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 40% at 104.500% prior to October&nbsp;1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional redemption:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Make-whole call @ T+50 bps prior to October&nbsp;1, 2024, then:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On or after:</B></FONT></TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2024</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102.250%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2025</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.125%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2026 and thereafter</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.000%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 1.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change of control:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Putable at 101.000% of principal plus accrued and unpaid interest</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade date:</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;28, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T+8; October&nbsp;8, 2021</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is expected that delivery of the notes will be made against payment
    therefor on or about October&nbsp;8, 2021, which is the eighth business day following the date hereof (such settlement cycle being referred
    to as &ldquo;T+8&rdquo;). Under Rule&nbsp;15c6-1 under the Exchange Act, trades in the secondary market generally are required to settle
    in two business days unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes
    prior to the T+8 settlement will be required to specify an alternative settlement cycle at the time of any such trade to prevent a failed
    settlement. Purchasers of the notes who wish to trade the notes prior to the T+8 settlement should consult their own advisors.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144A CUSIP: 42226AAA5</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regulation S CUSIP: U3827AAA7&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISIN:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144A ISIN: US42226AAA51</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regulation S ISIN: USU3827AAA70</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominations/Multiple:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000 x 1,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bookrunners:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.P. Morgan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wells Fargo Securities</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Truist Securities</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RBC Capital Markets, LLC</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Managers:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Citizens Capital Markets,&nbsp;Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MUFG Securities Americas,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BMO Capital Markets Corp. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capital One Securities,&nbsp;Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fifth Third Securities,&nbsp;Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KeyBanc Capital Markets Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TD Securities (USA) LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Huntington Securities,&nbsp;Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regions Securities LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bancroft Capital LLC</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>This material is confidential and is for your information only and
is not intended to be used by anyone other than you. This information does not purport to be a complete description of these notes or
the offering. Please refer to the Preliminary Offering Memorandum for a complete description.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>This communication is being distributed in the United States solely
to Qualified Institutional Buyers, as defined in Rule&nbsp;144A under the Securities Act of 1933, as amended, and outside the United States
solely to Non-U.S. persons as defined under Regulation S.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>This communication does not constitute an offer to sell or the solicitation
of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*A securities rating is not a recommendation to buy, sell or hold securities
and may be subject to revision or withdrawal at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any disclaimer or other notice that may appear below is not applicable
to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication
being sent by Bloomberg or another email system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ANNEX C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Restrictions on Offers and Sales Outside
the United States</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with offers and sales of Securities
outside the United States:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Initial Purchaser acknowledges that the Securities have not been registered under the Securities Act and may not be offered or sold within
the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in transactions not subject
to, the registration requirements of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Initial Purchaser, severally and not jointly, represents, warrants and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Such
Initial Purchaser has offered and sold the Securities, and will offer and sell the Securities, (A)&nbsp;as part of their distribution
at any time and (B)&nbsp;otherwise until 40 days after the later of the commencement of the offering of the Securities and the Closing
Date, only in accordance with Regulation S under the Securities Act (&ldquo;<U>Regulation S</U>&rdquo;) or Rule&nbsp;144A or any other
available exemption from registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">None
of such Initial Purchaser or any of its affiliates or any other person acting on its or their behalf has engaged or will engage in any
directed selling efforts with respect to the Securities, and all such persons have complied and will comply with the offering restrictions
requirement of Regulation S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
or prior to the confirmation of sale of any Securities sold in reliance on Regulation S, such Initial Purchaser will have sent to each
distributor, dealer or other person receiving a selling concession, fee or other remuneration that purchases Securities from it during
the distribution compliance period a confirmation or notice to substantially the following effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Securities covered hereby have not
been registered under the U.S. Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), and may not be offered or
sold within the United States or to, or for the account or benefit of, U.S. persons (i)&nbsp;as part of their distribution at any time
or (ii)&nbsp;otherwise until 40 days after the later of the commencement of the offering of the Securities and the date of original issuance
of the Securities, except in accordance with Regulation S or Rule&nbsp;144A or any other available exemption from registration under the
Securities Act. Terms used above have the meanings given to them by Regulation S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Such
Initial Purchaser has not and will not enter into any contractual arrangement with any distributor with respect to the distribution of
the Securities, except with its affiliates or with the prior written consent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms used in paragraph (a)&nbsp;and this paragraph (b)&nbsp;and not
otherwise defined in this Agreement have the meanings given to them by Regulation S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Initial Purchaser acknowledges that no action has been or will be taken by the Company that would permit a public offering of the Securities,
or possession or distribution of any of the Time of Sale Information, the Offering Memorandum, any Issuer Written Communication or any
other offering or publicity material relating to the Securities, in any country or jurisdiction where action for that purpose is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>hqy-20210928.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa2BibOdzZR+mYkxtmB4bSmK/yYq5n8TOSN6bUqWwe4I -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:hqy="http://healthequity.com/20210928" elementFormDefault="qualified" targetNamespace="http://healthequity.com/20210928">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://healthequity.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20210928_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20210928_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>hqy-20210928_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>hqy-20210928_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://healthequity.com/role/Cover" xlink:href="hqy-20210928.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://healthequity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>tm2128876d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hqy-20210928.xsd" xlink:type="simple"/>
    <context id="From2021-09-28to2021-09-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001428336</identifier>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-09-28to2021-09-28">0001428336</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-09-28to2021-09-28">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-09-28to2021-09-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-09-28to2021-09-28">2021-09-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-09-28to2021-09-28">HEALTHEQUITY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-09-28to2021-09-28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-09-28to2021-09-28">001-36568</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-09-28to2021-09-28">52-2383166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-09-28to2021-09-28">15 West Scenic Pointe Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-09-28to2021-09-28">Suite&#160;100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-09-28to2021-09-28">Draper</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-09-28to2021-09-28">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-09-28to2021-09-28">84020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-09-28to2021-09-28">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-09-28to2021-09-28">727-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-09-28to2021-09-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-09-28to2021-09-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-09-28to2021-09-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-09-28to2021-09-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-09-28to2021-09-28">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-28to2021-09-28">HQY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-28to2021-09-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-09-28to2021-09-28">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139818786244120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 28,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEALTHEQUITY,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001428336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2383166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15 West Scenic Pointe Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Draper<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HQY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ #80^4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ #80^4P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  -
MA#Y38O$_B.T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  -A#Y3F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  V$/E.ERL.;
M5@0  -\0   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  -A#Y3GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2128876d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://healthequity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2128876d1_8k.htm">tm2128876d1_8k.htm</File>
    <File>hqy-20210928.xsd</File>
    <File>hqy-20210928_lab.xml</File>
    <File>hqy-20210928_pre.xml</File>
    <File>tm2128876d1_ex1-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2128876d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2128876d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hqy-20210928_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hqy-20210928_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hqy-20210928.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hqy",
   "nsuri": "http://healthequity.com/20210928",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2128876d1_8k.htm",
      "contextRef": "From2021-09-28to2021-09-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://healthequity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2128876d1_8k.htm",
      "contextRef": "From2021-09-28to2021-09-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-21-121247-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-121247-xbrl.zip
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M ?\ZBFI++&:2+#$DCGA,GJ#&Y,DSQV22;-$GBI1PN<+=GF.W(\$GS+];+E@
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MY3^JB'PY5:THBD,H]7Y<:"9)AWN1ECHIZGU2R1;6Y]A#D,?*Z1RZX;5M!_8
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M$#"K?A[,I[I'O437T;]RJ12".*/SD(@',#C@L=;V;VM ,#1XN/,WFDW @B_
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M'7GMT?[5R!/A;[5W":R&\"-Y\2N&+:Y1O8\3OX)N]K#?=]X/;D%>+UYN+:J
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MEC8;S8Z2S9LO1*SNWY!F#C^M4,5 '*M6E=6K"HFZ6?(!I2B"*Z()*$P3T.]
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M?7"43[?.MT/@6)C=FM&P6F/M_-9]3ZC\HQDZ%^<<JUFRLP]O L)NRFBZ'/
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M*E9*:3F:(=DLV$[^Q\,\[>>?]K3[!DRW;$O9-,ZD8>5]P-I$WQY7*8->B6Q
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MG(?."='?%^X;*94I%K F-6)5L2TX0W"SNH4C"R-=5BRYQ0R+$?1T6^'(VZK
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M@@5Q0:";VCWW7U':S!.RO_>UN4+V][[Y0CZG+EY_^M(ZX#GH W&<[=1PMC?
MO*6>[A,Y12C=YMI!_+4B2Q0JBZ#?5C3Q!Z[TLX*3\#S623=I/0?/GB4QIQDC
M!^\5$XP#XHLUU:'0R&<&&C&E+DGP:Q)E-75>%ZCEX&U1UJ8$&I]G(H;RU2&[
M'?:?/W^J%9E?3]X>'OIJ3,5@_2[@Q>_REO[,&5+4#.HUB,IBCB% >/-1EN;4
M$DENQ%>WLD1_/3E[??0K_K(Y&)2A128_E5 :G"'&"7:C04W3WQF* *H;-R ,
M5MYSQ.2?)J'I"S-H([$A1+2(7?J<$,9:NSI95/I$Q FB_O%QX"%K6EKY#O$8
M&0W%*/QB&W@Z29O:8""&W)PGBA>:7%R@$5'Q 2D4<@"I;N\"+H?-/#<-H*)L
MB6VT@(YL:(YT$[V[;V6 ;GO,#W(+V_4&Y'F>8.<#E\@<Y* 1XI%AE=V>Q9S4
M6C :L%%G%,<E:3UUDB6+BR)/@KR93S#;,-D!DRAS5\"O=7%>1HL+--HY]"V+
M 98]W40)'=&'P!@&DI!HGAAC<Z;2#D3<4?;G1515V!/+?B$)TE,,*9OO$!#(
M]RNBPPQLH&*><%ZCQ,[ECA=>2=S2,]H$@9 8+B?!4;]=665GZ9CY+!E'VC[
MK+S+&_F9N=1X=$:>,Q5$IX9%CB.\T'GTXI@!8NYA$!HZ<1D0ES&8^;KW*5O7
MBS1ACV.J?=X< LVHXQP9J?[V&'W9IQ>.U:9D7!"F?31/D950!@YV3:M:Y,\Y
M4HZPJ8$$VZ\&7 U[(=BW)W&;,B]X]I0B_X%,!6 CTJ+S=D4D$\JMM8[9C!/R
M)I!_1!J'DIWFV(0)''#_8D/4@\9[6^"A-::;UI7F1K$"N0XZ=_%>]6:T6N/$
M)'-YU<?$AA@]=:U5'K)-G.81EEA'M329Z-:UK9[&>#0\C^L0PB9Y>&MIA?R6
MURIP_]%QX0ORO4APP \(&',8)5$MOA+7@8-Y"LW=BJ-0^%OW/KV^H2X<]"4V
MKC+W _)WD."!+I-V(;JJ!/;6=SP:\.N;0 5/U*O'[W%."E[M(B*^2GY50J6W
MO4DH2=/4^*D<Q5"<+OR!L=>M<U' *B5O6A>L$3&[]>B4C+NT4+E8TNZY;P9[
MTFRU('?\H+*XBB^V;@T:4'LG6R^__P;\C:RKYC.55F#R:9JK"FGL $%T/C6_
MX:;B#F+CT5 E@H8^;05;,^XN2A3(?V_3L:#XG2-BDX:JH+2\)E"]W9_6LD_%
M41S_WY*NL%-;=BD_6<G9."!;F!D>+L[;E7A>.X"P;0P2T5>"MKK"(NW/W=/=
MX!@[S-8&2E$4%&0DOS9 0D@Z_ ;6:W'T,V1R5HP(IBJ<9FTL_7KJ8\^:$D*I
MW%0%*+D41FK !%?#2L/$9,-*D@U]U&L_V9QPJUB%D2QE5D"X+3<'A4UAJ=+J
MF\JTUQ%IV57;N_6?0\@-(+94<>.=RJV-_.@HW0I32")')5Q_2NR!X%[ DL*M
M43ZO+9O)'W#=2=Y_/KJA(W3_JW.$[G]SA'Y.47WY&9+"D(,P'KI+(M\,0ZI5
M;Y=*8%.5:0=^E79A[+25>"0^MK&/;N"AQAKS3V4F*(&+3-)5_5E]OYU&.UQ?
M-1[=S/ TYAQ<,#?PC,CWC0\CM4M.W)U<LNRSH*5E),>EN5J"YB FY"I*DMCD
M::K< -U0I-D;+$A[C]IS=J ^WM,N$9?<M:I,P4DOXUFI'1;]2J]G_TB^K(+Z
M&YWTJT^"5'06?4BJGD8TP_X0;O4!-"N^_9#=_8C5,I7,?N3Q()#0J2@JYBQ%
MX%'RHT0?@#3JILR5AX2S>*0UZGC$5X."4C3G[,*FWKYR4'5HGUXP29!RJ9RM
MJA/7PFX6I:+TXK7L-L08?7F9],*>4X=W&^D )H.U ^RU<PJ2*VWPO%"W577)
MYH^K>8@^C$?H2)RF!* N60R,A<U.U#7Y>\19*I@TI>'T  BO1E%QC#PML;*X
MKV6= ;=YJ"6_'SY]R:^D?'(:QEMVW&Y8_&.SFZF0Q:2.2BD<(B57H74%NP0O
MO_+<0"E/R+9%.&0\%<;Y*4V.3>$Y'V\JSG1)<2H,-, H@&H,G]@@3X7;*2#$
M#-5>MK./O<:/@>W[6*]HM%A<JQ5D2POX>)33U0T;S29B$@M&U?!G3&P:2E0A
MM\%U$7;:K,U3<VX\KVO[70//V]J?AETFEX4#/?-!T&;.@VFA-A2YPX"8W-F/
MI,B<R]HJ>0$R4&:8E&HJ%6@KGQP,/=AFLT\P62]/KH1HB%+]%M&6#KRZ-)V2
M=/-T(PP,]\3UQR.708K2AKVGU+^=56]_SM?G'M3%C@OO<E//3?6!&,/'NNX*
MW7 "(W!9:/H>R/I_H))E^5D<KV^H#?4Q]YT6L0+6?;<[]60I'C1J4$TZ$@(&
M%,NDXYM<I480DA;RLJY;JX/IM@KY(/415UHX!!0G6\%Y[).HEIORFTT,12"[
MF(F"A9*CM=&W'&%[/5C8>8NB3-]V/HUO&+=_[4G>QSI<:FF#4?L&C5A*"#5Y
MF44KY*@=>8Y]?"6NN(.OSA5W\,T5]SF9][\^?7T0HUB,1Z_SR[0LC,8,)QM+
M=CB*YCUD L1[7B)"Z<ZTR(KR1[2"ZX1:/?$[UYH36S9=A=NSNW0MZ4S2ROU;
M[Q7(**A-WJ+0S_KS$Q_ RF#8T#!02?$<UO6PL03^LIC/"WJZEPNV*+*L,=I>
M-^7\@L)A*H4EFB4&GRQQJXP_F40;4$E <YLF7IHB%1F@@>QGQG.OLE::68TR
MB^NM*./,99D1NA@F4\DM[Q(+J<"2#H=LOYP%OT;_BLH8:U4,=V]76KF^OM3;
M3)--.X\P#+:N;/[#9:*K([E;[D#BIZB#X8"^:/$@+*"Z41.+TF&?.5^0\8MV
MP,NZH\=5-O;;"N,-)O9!30Q#9_4MIG<8L;Y9AH<W"]3%KCPZ,O9L)VZG<B?,
M6&] '2:9A I@6VK8-=-)AJI$_6P26/NE8B!2X3N81X+]A:^72&+):X,TD@X%
M!6+B984I$J$4O7^Y$3.QK,HPV3C!Q*LI4ODE/:-BP%Y7UH[C,)A:!>O2]E%<
M1$BIG;74,_4=%2Z4:O.G34+?/CZ,\WRT\857P O/24*%&U7:!!L7VL":K'9M
MJ#2A 2_'QWMQ+&N1;6('K@O!"T4XW+L^,ZB34.+9.=?TVA)E<?UY#QVD)H$V
M\MUN$E-"VRBK"@?4J;(V#-J,Q6+#;2HY2Y\>F=:,/-I3MHM.[2)GO($*Y(<M
M7_NW_;V]<&]OC_TZI6OO*N#EBH%L4M) ',:S[F;1E \,^30KE-%FU ,VVE E
M=5OX=5<W;!],RYQT^9QL4-_M6J%(;L;@B=[6105:-N%XU).$XOB@BE=N0H#H
M1T*;M::$65-5&2U2HK,/=!#J3M)^A*UHNFOB[--[;J;>R(:((FM$_)^^%D\?
M:3!8 AF/+(7H9#O;5163B8QZJG76MD+:T5>M)KLQK:JAD$=%TP J'@CLW@G"
MKZ"VK0T8:B^[")E'\OD4]J?ZQC.N*%@S&&HHRFT)(F(ML>$HA02SJTW'RGGY
M[<-)D%Y^S(Z82)9L!XA*2@MO-$\J@_4Q3TL'1@_S9Z26!#3/ID*Y>D497@)[
M$-OP2,\2RWH,! ('!R(U##W#"7N3R/N4DY(!1N",Y:8>9$[E()Q]&5D-;3/V
MYJNC&RE=7GTP7F''W4H,UN4GMZ+&K'+@J]S+WJ-LK3>I(]*^<^S4D,RQ$(TZ
MAB)2 .KC5U%%H0NRBR,&_8!%P'8(!@$$'0984?V!NY<5KEL-J[@4A^=*0)*P
MB*%AMTP+L46"F2E),]<':UHV6+.09N:DS$H3(N G,_*DN]?DQH;6!#^/L X)
M#,:83G$U >.@D&16\T%26?&-<R<=Y0FX4]1.#G\NHS@M(K8<U*43^%%*).,2
ME!)Z4A-;GP4?)D'107#0<WQ B:D!%.O8@.CT!@NO[-_3:L$#"/'POJ<_JB19
M$+]>-/,%?0/[AO.!%8%MKVOZ#I3(>DE_8;K"!0DL2@O]FQNOPQ45BF9Y]/2"
MKS6/1%]W4?&?"?<.,E\C=BC^C7I;>EXR#\>6N6G.G%SR-]@[HWPI(1\2N9#8
MB+N:9CMITDQT9:QX@[U_0%UI]Q]]=8[J1]\<U9]3R9Q,[E3)/&I[A%^_.SD]
MY+"B]1%0YUD3)S.MI['$. \'TA!/V4G+MS_:>B0/$L7NM7G4NZ06ES'8[""\
M;*KH$D&C)67QV6.=LJA+&FBLOA?4)8OU:'7SA"MF64F2YQS9#,S@%^!B"\._
MMZ0$%$64.(Y<:RMC,V/]DGMJ%+ATS@!=]PMJ=U24H(2+^;C!<CW>?^PTX!C4
M2%)7)(W'5XE0O-F1@.0$+26M+EBV*<2FEK)HW)1F(V4]7"!TB[M(1;I^'39;
MKS0.1\P/]:(>)S,5K5*'#IMJJ@(%/;6)!E5G$P@=4F.,:C)I:G(@4*(":VA$
M(/;%N)J>I@BFL1JN4DY7)VXX!75N37"W)^N=<[I(C]U-%^F$A^S:CVQTLA[O
M/<7O>)IH _B_/G_V1%-2Z'?B;0.<4[E<AAG*'ZP?0S=,X63O5D>Z2/:K8"C*
M* 955/ P+ZEH$768FZC^SOEP[:4U:XM;C)0\'M&TC"_/=HW@I\T:=NWI\M?.
MB3S0ZX@O]AG<WH'=!HX^X2K,0?LU#S=(7XP%<O-G(RNR1R5T+H *UKNB^NXM
M@[E1DZK)>IJIS\=5NXH0$4!*Q-BQ#%()@<14J3#V=#2L#I3%M(A9K_<]A"VS
MUPU"R';6H.ZW<DALMO*8@NL.Z84JR)?=I/MJS4^(2-^2K)(\O5( T!$1O3'>
M!F3S!*I82&\D<Q1,G8&!"'-W1>3K)!Y:X7S*QC:T(&\K/0'$"/>K0SY,ICL=
M!O)$5%7#IX.J"6D9D6"DS37>CE.\=*Q"^'&9D%<'9T<Q'RNR-F(9CQ]M39T\
M)L+:]CD#I]EH'X?>:;J,3Y-D[' .(!Y=\E:LSVOFBT/-0J]WS,>CK4O+0E?D
M#3G9S+_ZHIX&#@*$9AW231WJIC@E71/V^2.PB@01XT'OM8Q8-_PDA2"=-+S+
M,C,B#/;TS--F[KY_]<N1;3/=2C5D62\'29HZ;JLJ2HX""LTI1YBAF3E<GXJ(
M+TEW$ZK94-#L[6]%VUJ18\*16,UE.^ ED113L(NUC6PYZLBH;3\E ';OD)J;
MQ!2X#E;$4@X<__I6N,0KT64D46P)>VVU+M<DO6X7J 9@,&!JOG%F2):#SF'F
M"P:%Y37D&OE<;D3OV+/.>?%G!>**4/W5)2E1*P\OO.A]DBWMR?T1SLX'"UAC
MAP,D4Y*[M^T!L\Z\68N86P4@E&".*P-<$5>FTWNZ9UZV_E1JO(-96F'&R5*@
M4-<&C:@F2L9 H[9C-7W:U(!IA/+"E1"H)F8T1S!)S#40" 7$1,4=5:-D1(/E
M^O5<-0WS/CFJ".0Q;P3 90%CV"F=G625=A>36L?^3;,<_/"S[:&C>LF<6AS2
M_;VGVP.+2@R&5E6'PZXQNPU6\\&XB1Y_=6ZBQ]_<1)_3332=WJF;Z-@",5!7
M5<)Y;J,H?BI@)^-O0--!C%+TW3/D.;Y/V*@"CS#0U(&/.V<9IP+\@K&_LPW
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M/5H684KT;-N:VCM.1#-41D I($I22V9):@I2^YPP<8HDB[9&M1N\<@[6'I7
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MYB@]V/O:'*4'>]\<I9^UB\H=JWPX7N+);0:TJQJKG,R&%0I=9Z5Z<EE-I+I
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MB]T V2P_"?E:62R"7][^QIPL*Z:4:.#X6>?V?JU@2(7WE0(+'[Q:*]A, ]C
M_AA4 +!5]%>J 7PD7L!&/OHWR3ELR,E\D<2IZ7MQ(JC+7HNZPJ0&*YJBNC[J
M=$S;ES/$7(/F,?8Z#%6+0XHV$K1<^WZ075-N\!,7BQK51?1!<YQ1XKTS;@H7
M"H)=45J4HHU0ZEW15#B@?X2]J-.,]-A?E-6*>:[(M#!HV@K*6KFN$H1XDL5+
M\[^;?.JO%D=H@3\,+@&P@++NK*HLX$VG'@S.O!.N_YBI/]"#^Y$P#FL/[B]%
M$5-A *$PM+JH7EL9C^A[V*XX6J[P97IL.$$?AMO2\8AZ.%M<B/7^:MM]57FS
M?&@V>(:7MV$],%/,'?235Z7,((^C,B992H5F-2;A>AFL%M>$LF9AKC@QCX<8
MKB%.["YDW ,EV<^"6:#XJ<U'VPAC(/@&,?"Q&W)"HVD$C51M19N=V L[,B9N
MP KEX!S&4USZF4ANOL 6;<0#X;M0.U;'HVX&9'!6-A6("]=)N4,XMSXH7A5[
M+0(?3ET\V@[I@1+?#3 #UA+<:PL(C!0U@;5$A_0-A)>5/2N\A AX#*I/:$P*
M-#OPLG3>9/ Q*9I*:F8Y&</FI ]J>KUUU%@/I."0S!0#/4-7NQM-IV4C1-GD
MBRB-"08 ZW1#U/ 2G7D>S3$* D+H2L#E).88=BA>'A1@H#J4L.9\GM86_Q?V
M'X&1IW $8%UT"F//< V"-3T?4S120AERL\C2)*\D3Q"EK\J0=Z/L#+($68QH
M'@_TP-P8=6!]WPCDB>\2B4_YVMY1D7-7JMH4@*^*1H=B.=M'=38)"]^:^5RZ
MT#O4"?P>"Z00(@#]D7"311 7_:UR^4&<0[5PS>LQ$W1-5<_7E[5SX]+A:S55
M/#9>Y5;$>SV=K,HUV=BKQ/KSS+2$]LH4(J\'[G7<ZO>?(C9T9#_YZAS93[XY
MLN^4Z1RB1L*NV4HECW0.GM&AQB,\?G UJB43Z16:9%4B8-V='"UKI\7XA4$$
M]' 2G22@7(?*%L^A19]CNL>,XUD1O^&:Z2?K0WB[]Y<QW$14/+N-"M!K2) _
MR3:<YZJ5(&[.$>(&4P_J(M=H 0]KL>^\LK&SMH.0#$,@?RO*6O\N4M(%V5MR
MB1YC_(2GEZPB>3=?@&B@(,7+>8:)0?C$GK[=80N2RJ"'&//<UB/:43$XD>EN
M& 97%P5C3A=9Y56RJZK@+@(2MWORH%:?]!AG@KGD77BP9RYLH;"B\X_Q)K!@
MG?$0K5535!7.;II%Z9S2[>; _B5I%*:."";2#,C4^3M ;D1PJ,5+J3I;:@T'
M6&5&H9:6F8?X*<#.J #>5M[!<N6)-$V@1%;N99YB0H&-#ZCNF^(!I;&#)@4K
MRA:;K+=]I7T9<UY^X7;(9,- 7I<<9>#F5B7BX.$$$6H#7X+>H@F!,F)V 2/&
M=+L0E;BBR3F5TJUO >>EV.&NK8'$D/[ LL6\BD-VQ<<U]]R2=5U7AD%Q(BIY
MFZ=5)0\U2V"_LPV8:BDQON5NN('I$;QY7S._OU++PRZPG'!2BEE46F(:."@X
M975,X-ST$$^P">WT+>+*ZW NC-$H^@=EOG 6#65P(CE@'-"<I1:VL0.U(&+I
M,*>.C6,QHUT,H@72H0$/V%/-6],R;^ \8H \6UIX&MG9!RI;[Z[,>DBJ#ENQ
M6KKVPQ4)+E&H)2D%:FLC9\-U0E5[N8<:/'CN;S\@]E&B5D_?0P7S7.P;P!Y^
MI. UIZ8"-LJNR%JL?:S[HK6KEP.U$ ZH2)!S)LA/<N/M:G7$WHPU]<@V9N"?
M@S\%+?;$V%1#_&F Q=P*@^IQOV _MC:#NH:,#FY)1-/N?*R,1CT6+%6\FR1B
M56/ VJ*/J1HC(B]:*[T-X@*M+&>98=K%A2/54'^+SYVE,_@+%S,A06R*'ZZ2
M;*9OM+P)#B+H;7"]W(^/XH^J-LAZ[Q$2QVN4\38C#++@&-& Q4XS90&;[=J7
M[87=T.?V]*OSN3W]YG/[(BOM-\C?J].IQ.^IVT_<E#XVT@GC>VC3,=2&8PNT
M;D4V79I?)E4MD;YMD;%<^STG;X-M,3@A<<)FH)BBGL4M,-8>J+HM7?>T.-.<
MM.('ZD0SP3'L410TU" K#6@Z6V4IV$(&)RQ3N[I@E&_I"O1M"=_<EFGU=>(V
M:-PR,U"]YD9JK)C$>*3?;UZ.O7CD[?;-3G:O*!N;16F&F1FP(KGN1]MYK$P$
M=5>4 0D*=Q"(XA)96OU(DB7A)QPVA7A8XFRRTL9D-'A&K.MI6$^*,AJK-\-L
ML^1O(+\I9GUN:44$>,X,]ACG1EE8$L3'- "T=2NFO!EY,[:M<B/+P0F5K44+
M\0N)1/'GX55D8VVC90PV7$5248,NM:F& U2NUUIM6);!Y=X-[/'F7C[F5%L?
M_>JCV#<:TDJ];%):D32)A]>DUAWMAA<-U+"(%%YVWZ\I\>H9VQ::-_0LZAWJ
M]\-K=<#KWDZ=@<W+6R]1@\6^)JZX?6@HI#>2%PHG7W%?U(P5\/;Y[^3'>C;3
M,T>&?4N']&-;/5&CU=9>6]X['BTB/OY==Y])9.R[+S"W#3LNAQ_H-I/!.NK"
M,%O[)G)#&E\CD&S>1[)B!'076N>B7,CAYQTB8B+PJRM+5&P?FC5@P3@X9GM*
M9/GE0GM=SVB:G*QZC>#;NVM&CU:/&(^Z,YHW=>,<]-9ZXP:-Y?*% F(8>A,R
M561? GE 7D6UD34:76ZY9.IK\3*Z4W_AP1CT'PHO5TOUGS+%W8;0RT1DXGC$
M+G'#R(/H$J9B<&<DA8OL\CA%BP0/)/%::>P@>0X\Z@*KHO7] TOV@GLT7&H0
MYCS"4";!1R=^U^!A70D!RL  <_=MFS)VL ULHZV-:$-^8GKU@360&NEQ9G"2
MC4;.%$/)W ^&PK ZKSEN6.Q,D<HH8E"@0$;KG]<31V42T% V@VG*7=?GN^/1
M";4#66,KKQ21X4 HHQ6Y,+Q#?2OF*DYR/-+9U\3$4<I*?O @N_-[BE8(I8Q+
M@F FN)$>[;#K2%=3;:& I\0Y0CZ"1Q!$$?G<]'"VMVD4.-_N=E8F715IV'3N
MN Z3M0R*$OQHI=+Y!*0)<A-3$ZHC.;O!H:%;?\8S<9)\7'2/0DSL730=2,@;
M,N!74ID"ME6A[Y#ZK]VWN\%OE.2O78MOWAS9]PU,QLL>;KDT3:7:9G[4GDEM
M@K:S<F[M$IG=X&RM.NG3-;>8LMGN M.H3@@CR C71QT(]['5#1@,'Q2'Z4P>
M):@X(@1%72HE&Z.D#NP1X6!D#CS,+/8"S#U@';,56IY!\=<><0&![DK!WE@L
M^F^ULW893$SZEY7*>E5*.\[= &QAG)U-Q14C(CDO2",6+QR[RFOVLI)P[%>#
M/5%&.6>&ZZGK]>3MT1S2&'$A.T><CH]A.E'5#WS6\C .D]%'DA"WTVMWE(;U
M<FV@6AN0DN*;<-"ZUJ CC[S6UY2Y#7;A9-@\-=MKJT]]1-7UYICLE6&00]N
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M15_7YJA2:4H"Y^'6 A-(NH&:332S_F1ZJX"@FUW2[,Z;-*NYZFM61DW<9/@
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M>J58;D*6K+Y:Q*XA\J2@YJI!665K> ;CD8[->DGU1*T+T/L6Z$SOF 4$!K'
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M@IQ1^E3B!^!6O<3<NC;QVLH_B\V=UN';5HEI+,)31MLV)YBP7O"E<.NA26N
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MH(U.4<7JQ$Q 0JP!C, Q3!M< <>D<IMS? #YH2MTEKA .3,3: BF<H^OF\;
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M1R0ZD>)(D#M3]T84O5$7-!C5,"N)EU&;+3D4E2^Z25J#GGM/EAQOG72GT08
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M2P$"% ,4    "  -A#Y33)H7?@$+  #BAP  %               @ %V P
M:'%Y+3(P,C$P.3(X7VQA8BYX;6Q02P$"% ,4    "  -A#Y3.*]3.5T'   ^
M60  %               @ &I#@  :'%Y+3(P,C$P.3(X7W!R92YX;6Q02P$"
M% ,4    "  -A#Y3Q0Q2$$ 3   /:   $@              @ $X%@  =&TR
M,3(X.#<V9#%?.&LN:'1M4$L! A0#%     @ #80^4Q !]O&7C0  [7,# !4
M             ( !J"D  '1M,C$R.#@W-F0Q7V5X,2TQ+FAT;5!+!08
..!0 % $4!  !RMP     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
